Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer

The genomic landscape of breast cancer and its interaction with host immunity

(2016) Stephen Luen et al.   BREAST

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors

(2016) Ivana Sestak et al.   BREAST CANCER RESEARCH AND TREATMENT

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

(2016) Rico D. Bense et al.   JNCI-Journal of the National Cancer Institute

Spatial Heterogeneity in the Tumor Microenvironment

(2016) Yinyin Yuan   Cold Spring Harbor Perspectives in Medicine

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer

(2016) Rico D. Bense et al.   JNCI-Journal of the National Cancer Institute

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Erratum: Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer

(2015) Sidra Nawaz et al.   MODERN PATHOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

(2015) Peter Savas et al.   Nature Reviews Clinical Oncology

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response

(2014) Q. Gao et al.   CLINICAL CANCER RESEARCH

Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer

(2014) Congwen Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

(2013) A. K. Dunbier et al.   CLINICAL CANCER RESEARCH

CD4+ follicular helper T cell infiltration predicts breast cancer survival

(2013) Chunyan Gu-Trantien et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

(2013) Ivana Sestak et al.   JNCI-Journal of the National Cancer Institute

Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling

(2012) Y. Yuan et al.   Science Translational Medicine

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY